

	A1 - PLenary HALL	VICTORIA HALL	K1+K2	A2+A3	A4	A5	A6	A7	T5	T6	RESEARCH ZONE	THE SQUARE
08.00 08.30	Congress Opening											
08.45 12.00		CME 1 - Glomerulonephritis, Vasculitis, Autoimmune disease and Nephropathology	CME 4 - Haemo- and Peritoneal Dialysis	CME 7 - Electrolytes and urolithiasis	CME 3 - Bone mineral disorders in CKD	CME 5 - Kidney transplantation		Hands on course Vascular Access Catheter placement (Morning Course)	Hands on course Renal Biopsy (Morning course)			
12.00 12.15	Break											
12.15 13.15					ISS 0.1	ISS 0.2	ISS 0.3					
13.15 13.30	Break											
13.30 16.45		CME 2 - Hypertension, diabetes, cardiovascular diseases in CKD	CME 6 - Acute Kidney Injury	CME 8 - Basics of Genetics for Nephrologists	CME 9 - Diet in advanced CKD: What to do and not to do?	S 0.19 - CONNECT: future trajectories		Hands on course Vascular Access Catheter placement (Afternoon Course)	Hands on course Renal Biopsy (Afternoon course)			
16.45 17.00	Break											
17.00 18.15	Welcome Ceremony & Welcome Plenary											
16.00	Exhibition open											
18.30 20.30	Welcome reception											

24 FRI FRIDAY MAY 24, 2024

08.30 09.45	S 2.2 - Recent trials in glomerulonephritis	S 3.1 - CKD and diet	S 6.4 - New insights in diagnosis and treatment of DKD	S 5.1 - How to Improve transplant opportunities and organ quality	S 0.3 - ERA Registry	FC 01 - CKD: epidemiological studies with clinical consequences	FC 02 - Quality of life in dialysis and new risk prediction equations	FC 03 - Acute Kidney injury: trials and SGLT2 inhibition	Moderated Orals 1.1	Moderated Orals 1.3	Focused Orals 1.1	
09.45 10.15	Break											
10.15 11.15			ISS 1.1	ISS 1.2	ISS 1.3	ISS 1.4	ISS 1.5	ISS 1.6	ISS 1.7	S 0.13 Creative Labs 1 - How to turn your nephrology unit Green		
11.15 12.00	Plenary Lecture 1											
12.00 13.15	S 0.1 - The Flow study results	S 4.2 - Health systems and end stage renal failure	S 5.5 - Future of transplantation	S 1.1 - MicroRNAs and kidney disease	S 7.2 - Advances in AKI	S 6.3 - The kidney and blood pressure	FC 04 - Mechanisms of disease	FC 05 - About stones and ions	Moderated Orals 1.2	Moderated Orals 1.5	Focused Orals 1.2	S 0.11 - Learn by practice I - Use of anticoagulants and antiplatelets in CKD and Transplantation
13.15 13.45	Break											
13.45 14.45			ISS 1.8	ISS 1.9	ISS 1.10	ISS 1.11	ISS 1.12	ISS 1.13	ISS 1.14	S 0.17 - Creative Labs 5: Ethics in Clinical Trials		
14.45 15.15	Break											
15.15 16.15	S 5.2 - Specific tests in Transplantation	S 3.2 - Lessons from nature for the benefit of patients with kidney disease	S 2.1 - FSGS: current thoughts on aetiology and treatment	S 1.3 - Novel technologies to dissect mechanisms of kidney diseases	S 6.1 - HFpEF: nephrology and cardiology viewpoints	S 7.3 - Distant organ effects of AKI	FC 06 - Mechanisms of disease in kidney transplantation	FC 07 - SGLT2 inhibition for cardiorenal disease	S 0.9 - ERAC - Clinical trials of the future: relevant endpoints?	S 0.14 - Creative Labs 2 - A crash course in prediction models	Focused Orals 1.3	S 0.10 - Important Clinical Studies
16.15 16.30	Break											
16.30 16.45												
16.45 18.00	S 3.3 - CKD as a global health issue: a call to action	S 4.3 - Optimising renal replacement in the elderly	S 2.3 - New targets to treat glomerulonephritis	Biopsies in kidney transplantation (Pro/Con)	S 7.1 - Balanced fluids are the fluids of choice to prevent AKI in high risk patients (Pro/Con)	FC 08 - Gut dysbiosis and peritoneal dialysis	FC 09 - Diabetic nephropathy	FC 10 - Experimental studies into glomerular diseases	Moderated Orals 1.4	Moderated Orals 1.6	Focused Orals 1.4	
18.15 19.15					ISS 1.15	ISS 1.16	ISS 1.17					
9.30 17.30	Exhibition											

25 SAT SATURDAY MAY 25, 2024

08.30 09.45	S 2.5 - Technologies to transform kidney care	S 3.4 - CKD as a model of premature ageing	S 5.3 - How far can we go in transplantation	S 0.4 - 2024 pearls of NDT and CKJ	S 1.6 - Emerging concepts in renal genetic diseases	FC 11 - To dialyze or not, and when dialyzing how to do so?	FC 12 - Outcome of kidney transplantation: associations with adherence and age	FC 13 - About sodium and potassium	Moderated Orals 2.1	S 0.18 - Women in ERA	Focused Orals 2.1	
09.45 10.15	Break											
10.15 11.15	General Assembly		ISS 2.1	ISS 2.2	ISS 2.3	ISS 2.4	ISS 2.5	ISS 2.6	ISS 2.7			Industry Spotlight Session
11.15 12.00	Plenary Lecture 2											
12.00 13.15	S 3.6 - Redesigning clinical trials in nephrology	S 0.2 - Late Breaking Clinical Trials I	S 4.5 - Update on anemia management in hemodialysis patients	S 6.2 - What's New in Hypertension Management?	S 7.4 - Drugs and AKI	FC 14 - Polycystic kidney diseases	FC 15 - About vitamin K, bleeding risk and related need for treatment	FC 16 - CKD: experimental studies	S 0.7 - Young Awardees	S 0.16 - Creative Labs 4 - How to review a paper	Focused Orals 2.2	Moderated Orals 2.2
13.15 13.45	Break											
13.45 14.45			ISS 2.8	ISS 2.9	ISS 2.10	ISS 2.11	ISS 2.12	ISS 2.13	ISS 2.14	S 0.15 Creative Labs 3 - A nephrologist's guide to prevent post-transplant diabetes		
14.45 15.15	Break											
15.15 16.30	S 0.21 - Late Breaking Clinical Trials II	S 2.4 - New approaches to managing glomerulonephritis	S 6.6 - Diabetes and hypertension: what about sex?	S 7.5 - RRT in AKI	S 1.5 - ADPKD: looking to the future	FC 17 - Novel treatments of immune mediated kidney diseases	FC 18 - Clinical studies in kidney transplantation	FC 19 - Experimental studies into chronic cardiorenal disease	Moderated Orals 2.3	S 0.8 - Disaster nephrology	Focused Orals 2.3	S 0.12 - Learn by practice II - Therapeutic tailoring in the management of CKD-MBD
16.30 16.45	Break											
16.45 18.00	S 3.5 - CKD and its systemic effects on health	S 4.6 - Controversies in dialysis techniques	S 1.2 - Aquaporins in health and disease	S 6.5 - Treatment of obesity in DKD: new drugs are the right answer (Pro/Con)	S 2.6 - B cell targeting therapy in refractory lupus nephritis	FC 20 - AKI and TMA	FC 21 - CKD: screening and association with socio-economic status	FC 22 - Analyzing multitudes of data	Moderated Orals 2.4	Moderated Orals 2.5	Focused Orals 2.4	
9.30 17.30	Exhibition											

26 SUN SUNDAY MAY 26, 2024

08.30 09.45	S 0.6 - KDIGO update - PKD guidelines 2024	S 4.1 - Atrial fibrillation in patients treated by dialysis	S 4.4 - Renal replacement therapy in the year 2040	S 1.4 - Kidney fibrosis: novel concepts for mechanisms driving renal scar formation	FC 23 - The quest for exactness: estimating GFR	FC 24 - Epidemiological studies into glomerular diseases	FC 25 - Clinical studies in patients on dialysis	FC 26 + ML A kidney protective network converging at Klotho				
09.45 10.00	Break											
10.00 10.45	Plenary Lecture 3											
10.50 12.00	S 0.5 - Nephrology Pearls											

Renal physiology, urolithiasis, hereditary disorders & rare diseases in children, pregnancy | Glomerular diseases & general clinical nephrology | CKD - pathophysiology, epidemiology, prevention, progression, ageing | End Stage Kidney Disease, hemodialysis, kidney function replacement therapies | Kidney transplantation (clinical and immunology) | Hypertension, diabetes, cardiovascular risk in CKD | AKI, intensive care nephrology | Institutional | Plenary Lecture | Hands-On Course | Moderated Orals and Focused Orals | Industry Sponsored Sessions | Creative Labs